Spero Therapeutics, Inc. 8-K

What Happened Spero Therapeutics (SPRO) announced that the U.S. Food and Drug Administration has approved Utebzi (tebipenem pivoxil), an oral antibiotic to treat complicated urinary tract infections (cUTIs), including pyelonephritis, in adults who have limited or no alternative oral treatment options. The company issued a press release on June 17, 2026 and filed a Form 8-K on June 22, 2026 to disclose the approval. The approval was announced ahead of the FDA-assigned PDUFA date of June 18, 2026.

Key Details

• Drug approved: Utebzi (tebipenem pivoxil), an oral carbapenem antibiotic.
• Indication: Treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, in adults with limited or no alternative oral options.
• Timing: Press release dated June 17, 2026; Form 8-K filed June 22, 2026; approval announced before the June 18, 2026 PDUFA date.
• Development/licensing: Approval follows GSK’s development work and Spero’s exclusive global licensing agreement with GSK (excluding select Asian territories).

Why It Matters This FDA approval is a regulatory milestone for Spero: Utebzi is described as the first and only oral carbapenem approved for the specified cUTI patient population, which may differentiate it clinically from existing oral options. For investors, the approval advances Spero from development-stage toward commercial opportunities (under its deal with GSK) and is a material event that could affect the company’s near-term commercial strategy and market visibility.